

# Meera Mohan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704452/publications.pdf>

Version: 2024-02-01

66  
papers

463  
citations

933447

10  
h-index

839539

18  
g-index

66  
all docs

66  
docs citations

66  
times ranked

797  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances, 2022, 6, 808-817.	5.2	14
2	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e495-e497.	0.4	2
3	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer Journal, 2022, 12, 34.	6.2	22
4	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR TÂcell, and BiTE recipients. Cancer Cell, 2022, 40, 340-342.	16.8	35
5	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American Journal of Hematology, 2022, 97, .	4.1	0
6	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of Clinical Medicine, 2022, 11, 1640.	2.4	6
7	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Advances, 2022, 6, 2466-2470.	5.2	29
8	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multiâ€institutional experience. American Journal of Hematology, 2022, 97, .	4.1	4
9	Gender disparities in multiple myeloma publications.. Journal of Clinical Oncology, 2022, 40, e23000-e23000.	1.6	0
10	Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021. Touch Reviews in Oncology & Haematology, 2022, 18, 53.	0.2	0
11	Neutralizing antibody responses against <sc>SARSâ€CoV</sc>â€2 in patients with plasma cell disorders who are on active treatment after two doses of <sc>mRNA</sc> vaccination. European Journal of Haematology, 2022, 109, 458-464.	2.2	9
12	Salvage second transplantation in relapsed multiple myeloma. Leukemia, 2021, 35, 1214-1217.	7.2	17
13	Clinical characteristics of testicular extramedullary involvement in multiple myeloma. American Journal of Hematology, 2021, 96, E77-E81.	4.1	1
14	Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation. Case Reports in Hematology, 2021, 2021, 1-5.	0.4	0
15	Bone remineralization of lytic lesions in multiple myeloma â€“ The Arkansas experience. Bone, 2021, 146, 115876.	2.9	4
16	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, e20031-e20031.	1.6	1
17	Interactions between cardiology and oncology drugs in precision cardio-oncology. Clinical Science, 2021, 135, 1333-1351.	4.3	7
18	Persistent bone marrow minimal residual disease as a â€œhighâ€riskâ€disease feature in multiple myeloma. American Journal of Hematology, 2021, 96, E341-E344.	4.1	4

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift. <i>JCO Oncology Practice</i> , 2021, 17, 405-413.	2.9	10
20	Combinatorial treatment for unresectable unicentric Castleman disease. <i>European Journal of Haematology</i> , 2021, 107, 484-488.	2.2	1
21	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4019.	3.7	9
22	Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM). <i>European Journal of Haematology</i> , 2021, 107, 602-608.	2.2	7
23	The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4909.	3.7	5
24	Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106648.	0.8	0
25	Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. <i>Leukemia Research</i> , 2021, 110, 106714.	0.8	2
26	Metabolically Reprogrammed Polyclonal Autologous Rapa-201 Cell Therapy Yields a Promising Safety and Efficacy Profile in Relapsed and Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 2838-2838.	1.4	7
27	Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients. <i>Blood</i> , 2021, 138, 4018-4018.	1.4	0
28	Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. <i>Blood</i> , 2021, 138, 2713-2713.	1.4	0
29	Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. <i>Blood</i> , 2021, 138, 4091-4091.	1.4	0
30	Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2742-2742.	1.4	0
31	Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome. <i>Blood</i> , 2021, 138, 1627-1627.	1.4	0
32	Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1626-1626.	1.4	3
33	Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination. <i>Blood</i> , 2021, 138, 3804-3804.	1.4	2
34	Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. <i>British Journal of Haematology</i> , 2020, 189, 67-71.	2.5	35
35	Two Cases of Vancomycin-Resistant <i>Enterococcus faecium</i> Bacteremia With Development of Daptomycin-Resistant Phenotype and its Detection Using Oxford Nanopore Sequencing. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa180.	0.9	11
36	Intractable hypercalcemia in a patient with multiple myeloma: An infectious etiology. <i>Transplant Infectious Disease</i> , 2020, 22, e13354.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. <i>Blood Cancer Journal</i> , 2020, 10, 70.	6.2	27
38	Complete Genome Sequences of Four Isolates of Vancomycin-Resistant <i>Enterococcus faecium</i> with the <i>vanA</i> Gene and Two Daptomycin Resistance Mutations, Obtained from Two Inpatients with Prolonged Bacteremia. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	6
39	Late Relapsing Multiple Myeloma 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. <i>Blood</i> , 2020, 136, 11-12.	1.4	3
40	Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 8514-8514.	1.6	2
41	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. <i>Blood</i> , 2020, 136, 44-44.	1.4	2
42	Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. <i>Transplant Infectious Disease</i> , 2019, 21, e13052.	1.7	6
43	HCI Improvement on 14nm FinFET IO Device by Optimization of 3D Junction Profile. , 2019, , .		6
44	Draft Genome Sequences of 48 Vancomycin-Resistant <i>Enterococcus faecium</i> Strains Isolated from Inpatients with Bacteremia and Urinary Tract Infection. <i>Microbiology Resource Announcements</i> , 2019, 8, .	0.6	3
45	Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 308-310.	2.5	2
46	487. Severity and Clinical Outcomes of <i>Clostridium difficile</i> Infection Based on Toxin B Assay Results. <i>Open Forum Infectious Diseases</i> , 2018, 5, S180-S181.	0.9	0
47	The Mutational Landscape of Primary Plasma Cell Leukemia. <i>Blood</i> , 2018, 132, 114-114.	1.4	2
48	Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization. <i>Blood</i> , 2018, 132, 2415-2415.	1.4	1
49	Survey of Compliance to Infection Control Measures and Its Impact on Healthcare of Patients in a Hematopoietic Stem Cell Transplant Unit. <i>Blood</i> , 2018, 132, 5825-5825.	1.4	0
50	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1261-1266.	2.8	9
51	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. <i>Haematologica</i> , 2017, 102, e313-e316.	3.5	26
52	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. <i>American Journal of Hematology</i> , 2017, 92, 739-745.	4.1	36
53	Update on the optimal use of bortezomib in the treatment of multiple myeloma. <i>Cancer Management and Research</i> , 2017, Volume 9, 51-63.	1.9	48
54	Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. <i>Transplant Infectious Disease</i> , 2016, 18, 939-941.	1.7	10

#	ARTICLE	IF	CITATIONS
55	<i>Lasioidiplodia</i> species fungal osteomyelitis in a multiple myeloma patient. Transplant Infectious Disease, 2016, 18, 761-764.	1.7	7
56	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. Blood, 2016, 128, 377-377.	1.4	1
57	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. Blood, 2016, 128, 4516-4516.	1.4	8
58	A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. American Journal of Case Reports, 2016, 17, 173-176.	0.8	3
59	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. Blood, 2016, 128, 2064-2064.	1.4	0
60	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. Blood, 2015, 126, 2979-2979.	1.4	2
61	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. Blood, 2015, 126, 369-369.	1.4	1
62	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. Blood, 2015, 126, 3182-3182.	1.4	1
63	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Blood, 2015, 126, 4193-4193.	1.4	0
64	S1411: Comparison of Endoscopist Administered Conscious Sedation Versus Anesthesiologist Administered Deep Sedation for Gastrointestinal Endoscopy in an Ambulatory Surgery Center. What Should Be the Standard of Care?. Gastrointestinal Endoscopy, 2010, 71, AB154.	1.0	0
65	Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. EJHaem, 0, , .	1.0	2
66	Gender disparities in multiple myeloma publications. EJHaem, 0, , .	1.0	0